hVIVO plc
("hVIVO", the "Company" or the "Group")
Positive results from RSV antiviral human challenge trial conducted by hVIVO
Larger human challenge trial provides valuable insights for candidate development
hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals ("Enanta"), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus ("RSV") human challenge trial ("HCT") in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate.
EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has made impressive strides, achieving
These positive results highlight the significant role human challenge trials play in accelerating efficacy data collection and reducing the risks associated with later stage clinical development. With three decades of experience and expertise in safely conducting human challenge studies, hVIVO is proud to support groundbreaking research like this across a range of respiratory viruses, including RSV, influenza, human rhinovirus (HRV - common cold virus), and COVID-19. The Company looks forward to seeing continued success for Enanta and EDP-323 in the future.
Enanta's full announcement is available here. EDP-323 is Enanta's second RSV candidate. Zelicapavir (EDP-938), Enanta's first candidate, has already shown impressive results in an earlier RSV HCT and is in later stage clinical development.
Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "Enanta's trial demonstrates the depth of actionable insights a comprehensive human challenge trial can provide. We congratulate Enanta on these impressive results, which mark a significant step forward in the development of new medicines to treat respiratory infections such as RSV. Achieving such positive outcomes underscores the potential of this novel RSV treatment to make a meaningful impact on patient care. We are proud to provide world leading human challenge trials to support the development of exciting drug candidates which hold the potential to have a positive impact on global health."
For further information please contact:
hVIVO plc |
+44 (0) 20 7756 1300 |
|||
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
|
|||
|
|
|||
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7220 0500 |
|||
Geoff Nash, Camilla Hume, Harriet Ward |
|
|||
Nigel Birks - Life Science Specialist Sales |
|
|||
|
|
|||
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
James Steel, Dr Christopher Golden |
|
|||
|
|
|||
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
Anthony Farrell, Niall Gilchrist |
|
|||
|
|
|||
Walbrook PR (Financial PR & IR) Stephanie Cuthbert, Phillip Marriage, |
+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
|||
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge trials in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.